|
 Home
|
|
|
Back
|
15 May 2008
|
Alpha-methylacyl-coA racemase reactivity may aid PIN management
|
MedWire News: Measuring alpha-methylacyl-CoA racemase reactivity in high-grade prostatic intraepithelial neoplasia (PIN) may help to refine re-biopsy criteria and aid clinical management decisions, Canadian study findings indicate.
The number of patients diagnosed with high-grade PIN has increased due to serum prostate-specific antigen (PSA) screening, thus increasing the number of biopsies performed. The re-biopsy criteria are not standardized and may be refined by the identification of novel biomarkers, explain Joan Sweet, from Toronto General Hospital in Ontario, and colleagues.
Noting that alpha-methylacyl-coA racemase is a reliable marker of prostate cancer, the researchers performed immunohistochemical staining for alpha-methylacyl-CoA racemase and p63 in 62 patients with high-grade PIN on initial biopsy.
Of these men, 32 had no carcinoma on repeat biopsy while 30 had prostate cancer. There were no significant differences between the two groups in terms of age, number of core samples, or PSA history.
Overall, alpha-methylacyl-coA racemase reactivity was detected in 27 of the 62 cases, while all of the cases had p63 reactivity in the basal epithelium, the researchers report in the Journal of Urology.
Analysis indicated that patients with high-grade PIN glands reactive for alpha-methylacyl-CoA racemase were 5.18 times more likely to be diagnosed with prostate cancer on subsequent biopsy than those who had unreactive glands. Alpha-methylacyl-CoA racemase was not linked to any other clinical variable.
"These results suggest that alpha-methylacyl-CoA racemase reactivity in high-grade PIN aepithelial neoplasia glands may be of value in the clinical management of patients with a diagnosis of high-grade intraepithelial neoplasia in prostate biopsy," the team concludes.
J Urol 2008; 179: 1751-1755
http://dx.doi.org/10.1016/j.juro.2008.01.012
|
|
© 2006 CMG
|
|
Search
Information for
This is an AstraZeneca International website for healthcare professionals. The site is not intended for the following audiences who should use the links below:
Casodex news feed
Quick links
Features
|
 |
| |
|
|
